Why Alnylam Pharma Shares Are Trading Higher During Premarket Session

Alnylam Pharmaceuticals Inc ALNY shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Clumps of irregular proteins called fibrils build up in the heart harder for the heart to pump blood.
The trial met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo.
The study also met the first secondary endpoint of change from baseline in quality of life compared to placebo.
Patisiran also demonstrated an encouraging safety and tolerability profile, with deaths numerically favoring the patisiran arm.
The company plans to file a supplemental marketing application with the FDA in late 2022.
Five patients (2.8%) on patisiran and 8 (4.5%) on placebo died. Furthermore, the number of deaths in the all-cause mortality efficacy analysis was 4 (2.2%) in the patisiran arm and 10 (5.6%) in the placebo arm.
The patisiran and placebo arms had similar frequencies of adverse events.
Patisiran is marketed as Onpattro, approved in the United States and Canada for polyneuropathy of hATTR amyloidosis in adults.
Price Action: ALNY shares are up 55.8% at $220.00 during the premarket session on the last check Wednesday.